ASMB

22.1901.38%
SM

Susan M. Mahony

Independent Director

Dr. Susan M. Mahony, also known as Sue, MD, PhD, MBA., is Director of Catalent Pharma Solutions, Inc. She is Director of Catalent, Inc. from February 20, 2025. She serves as an Independent Director at Axsome Therapeutics, Inc. since October 10, 2023. She serves as Director at Altis Biosystems, LLC and Kovina Therapeutics Inc. She served as Independent Director at Horizon Therapeutics Public Limited Company since August 1, 2019 until October 06, 2023. She has been Lead Independent Director at Zymeworks Inc. since December 07, 2023. She serves as Independent Director at Zymeworks Inc since June 3, 2019. Dr. Mahoney has been Independent Director of Assembly Biosciences, Inc. since December 2017. Dr. Mahoney had been a Director at Vifor Pharma AG since May 08, 2019 until August 2022. She had been the President of Lilly Oncology and Senior Vice President of Eli Lilly and Company from February 11, 2011 to August 31, 2018. She serves as Director at Altis Biosystems. Dr. Mahoney also serves on the Board of Chordoma Foundation, a nonprofit organization dedicated to improving the lives of those affected by chordoma. She served as Senior Vice President of Human Resources at Eli Lilly and Company from May 1, 2009 to February 11, 2011. At Lilly, she held leadership positions and led organizations in Europe, the United States, Canada, Japan and China. She also led the global development and launches of several products, including duloxetine for depression and pain. Prior to Lilly. Dr. Mahoney led commercial activities for Bristol Myers Squibb’s cardiovascular business and worked in sales and marketing at Amgen and Schering Plough. Dr. Mahoney served as President and General Manager of Eli Lilly Canada Inc. since July 2008. She served as Executive Director of Six Sigma of Demand Realization at Lilly's global Headquarters in Indianapolis, Indiana where she was responsible for Six Sigma efforts in sales, marketing and the affiliates globally. From 2000 to 2011. Dr. Mahoney served in a variety of leadership roles at Lilly, including Executive Director of Global Development. Previously, she held various senior global marketing and brand development positions responsible for such products as Cymbalta, Yentreve and Prozac. Dr. Mahoney has many years of experience in the pharmaceutical industry in the United Kingdom, Europe and the United States. Before joining Lilly in 2000, she held various sales and marketing roles with Bristol-Myers Squibb Company from 1995 to 2000, Amgen Limited from 1991 to 1995 and Schering-Plough from 1989 to 1991. Dr. Mahoney is a Member of the Board of Directors of the Park Tudor School in Indianapolis. She was recognized as one of the Indianapolis Business Journal’s “Women of Influence.”. Dr. Mahoney received a Ph.D. in Pharmacy and a Bachelor of Science in Pharmacy from Aston University, Birmingham in the UK, which also awarded her an honorary doctorate degree. She received Master of Business Administration from the London School of Business in 2010.

Positions